Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)

  • STATUS
    Not Recruiting
  • End date
    Jan 6, 2023
  • participants needed
    195
  • sponsor
    Novartis Pharmaceuticals
Updated on 28 April 2022
metastatic melanoma
combinations
systemic therapy
measurable disease
pembrolizumab
nivolumab
ipilimumab
mek inhibitor
cytotoxic t-lymphocyte antigen 4

Summary

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Details
Condition Melanoma
Treatment Ribociclib, canakinumab, LAG525, capmatinib, spartalizumab
Clinical Study IdentifierNCT03484923
SponsorNovartis Pharmaceuticals
Last Modified on28 April 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note